Scholar

Lotte Steuten

H-index: 32
Economics 51%
Public Health 19%
prof-nancy-devlin.bsky.social
Will Trump's plan to use 'Reference Pricing' cut US drug prices? This #ValueinHealth paper by Grueger, Martin & Sullivan argues reference pricing is ill-advised & will lead to unintended consequences.

open access 👉 tinyurl.com/reference-pr...

#Trump #HealthEconomics
Image is copyright to Jane Doe/ Shutterstock. Shows a cartoon image of Donald Trump with a signed Executive Order

Reposted by: Lotte Steuten

ohenews.bsky.social
There is a range of ways ex-US payers and pharma companies might respond to President Trump’s “Most Favoured Nation” drug pricing. Will any of them work to lower #US drug prices?

Read more: www.ohe.org/insight/the-trump-administrations-us-drug-pricing-proposal-what-will-happen-next/

Reposted by: Lotte Steuten

ohenews.bsky.social
New insight: 68% of OECD countries formally use #QALYs in pricing decisions, but practices vary. How consistent is economic evaluation across borders?
www.ohe.org/insight/how-...

#HTA #healtheconomics

Reposted by: Lotte Steuten

ohenews.bsky.social
Argentina plans a new national #HTA agency, ANEFiTS. A big step for evidence-based #policy, but key questions on governance, transparency & legal power remain. Read more: www.ohe.org/insight/arou...

Reposted by: Lotte Steuten

ohenews.bsky.social
New insight: a substantial proportion of these medicines do not deliver their intended therapeutic benefits for the individuals taking them, due to genetic variations.
##pharmacogenomics #CERSI

www.ohe.org/insight/pharmacogenomics-testing-a-crucial-piece-to-unlocking-the-full-value-of-medicines/

Reposted by: Lotte Steuten

ohenews.bsky.social
Vaccines return up to 19x their cost, but adult #immunisation is undervalued. Our new insight calls for long-term investment to boost health, productivity & system resilience. www.ohe.org/insight/prevention-pays-off-so-why-arent-we-doing-more-of-it/

Reposted by: Lotte Steuten

ohenews.bsky.social
How can the #UK prepare for an #ageingsociety? OHE’s submission to a #parliamentary inquiry stressed that keeping as many people as healthy and productive as possible – for as long as possible – is a requisite measure in addressing a shrinking #workforce. Read more: www.ohe.org/insight/offi...

Reposted by: Lotte Steuten

ohenews.bsky.social
Kenya is making progress on using evidence to guide healthcare decisions. New reforms embed #HTA in #policy, but challenges in capacity, funding and transparency remain. www.ohe.org/insight/arou...

Reposted by: Lotte Steuten

ohenews.bsky.social
GLP-1s are changing #obesity care—but access, equity, and patient preferences raise new challenges. Our latest insight looks at what this means for #policy and practice. www.ohe.org/insight/glp-...

#healtheconomics #GLP1

Reposted by: Lotte Steuten

ohenews.bsky.social
📢 New publication from OHE: Understanding the full value of long-acting therapies: Less is more?

We will also be discussing this research at ISPOR 2025 in Issue Panel 116. Join us for the discussion!

Read it here: www.ohe.org/publications...

#healtheconomics #HTA
Understanding the Full Value of Long-Acting Therapies: less is more? - OHE
Long-acting therapies offer value for chronic disease, improving adherence and outcomes. This OHE report highlights HTA gaps, real-world evidence, and policy needs.
www.ohe.org

Reposted by: Lotte Steuten

ohenews.bsky.social
47% of NICE “positive” decisions now limit treatment to just 31% of eligible patients. A new OHE report looks at the rise in ‘optimised’ guidance—and what it means for patient access.
www.ohe.org/publications...

#HTA

Reposted by: Lotte Steuten

ohenews.bsky.social
Respiratory infections can cost UK businesses £44 billion a year—but how much is your company losing? Use the new Cost Calculator from OHE & funded and owned by Pfizer to get a tailored estimate and consider the impact on productivity. Try it now: www.ohe.org/respiratory-...
#HealthEconomics
Respiratory Cost Calculator - OHE
The Respiratory Cost Calculator summarises the potential financial impacts of employee absenteeism and presenteeism as incurred by the employer due to respiratory infections.
www.ohe.org

Reposted by: Lotte Steuten

ohenews.bsky.social
From the Archives: Our report, published at April 2024, looked at how HTA methods have evolved across 14 countries, highlighting key reforms, guidance gaps, and the role of international collaboration in shaping future approaches. Find out more: www.ohe.org/publications...
#HTA #healtheconomics
How Have HTA Agencies Evolved Their Methods Over Time? - OHE
This report explores the variation in past and current positioning of Health Technology Assessment (HTA) agencies in 14 countries, on five key methodological topics: discount rates, modifiers, patient...
www.ohe.org

Reposted by: Lotte Steuten

ohenews.bsky.social
New report: Analysing Global Immunisation Expenditure

Immunisation is critical for public health, but funding remains low. Our latest report reveals key trends in investment, preventable mortality & coverage.
www.ohe.org/publications...

#Immunisation #PublicHealth #HealthEconomics #Vaccines

Reposted by: Lotte Steuten

ohenews.bsky.social
We recommend a gradual adoption, international collaboration, and patient involvement to drive meaningful change. #HTA #HealthEconomics

Reposted by: Lotte Steuten

ohenews.bsky.social
The adoption of a societal perspective in HTA can help addressing societal and economic needs in the Asian-Pacific region, but its implementation is limited. Barriers include the lack of methods and evidence and capacity constraints. #HTA #HealthEconomics
The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region

Reposted by: Lotte Steuten

ohenews.bsky.social
Should cognition be added to EQ-5D? New research by OHE's Hannah Hussain explores whether memory & concentration perform better than a single “cognition” item. Findings could reshape EQ-5D use in dementia, mental health & HTA. www.ohe.org/insight/addi...

Reposted by: Lotte Steuten

ohenews.bsky.social
Canada’s HTA system blends provincial autonomy with national coordination. CDA-AMC’s evolving role and the pan-Canadian Pharmaceutical Alliance are reshaping drug access and pricing. Future reforms, including national Pharmacare and global collaboration, promise more efficient and patient access.

Reposted by: Lotte Steuten

epopppp.bsky.social
Another way to put this:

Musk and his twerps have exposed us to pandemics, broken science, stolen all your data, endangered the U.S. payments system, threatened air traffic control, and cut off HIV medication to 20m people in order to save ::checks notes:: 2/10th of a percent of the federal budget.

Reposted by: Lotte Steuten

dshaywitz.bsky.social
Great op-ed by @cmyeaton.bsky.social on the surprisingly high level of popular support vaccines continue to enjoy - www.nytimes.com/2025/02/16/o... - almost as if most people prefer them to polio, measles, and cervical cancer. Also: my @wsj.com review of her recent book-> www.wsj.com/arts-culture...
Opinion | Kennedy’s Anti-Vaccine Views Don’t Represent America
Threatening vaccine access is not only bad science, it’s bad politics.
www.nytimes.com
meganranney.bsky.social
🛟 That last-ditch chemo trial your family member was hoping to be in
🥙 The investigation of a food-borne illness outbreak in the next town over
🧠The study looking for preventable causes of Alzheimer’s
🧪The assurance that TAXPAYER-PAID-FOR studies & data collection see the light of day

References

Fields & subjects

Updated 1m